

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the “Announcement in Relation to the Approval for Drug Registration of a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Yuqing

Chairman

Shanghai, the PRC

15 September 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Pan Donghui and Mr. Wu Yifang; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* for identification purposes only

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Approval for Drug Registration of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement, or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, the drug registration application for the additional indication of Fovinaciclib Citrate Capsules (trade name: 复妥宁, project no.: FCN-437c, the “**Drug**”) of Jinzhou Avanc Pharmaceutical Co., Ltd.* (錦州奧鴻藥業有限責任公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the “**Company**”), has been approved by the National Medical Products Administration. The approved indication is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor2 (HER2)-negative locally advanced or metastatic breast cancer: in combination with an aromatase inhibitor as initial endocrine therapy.

II. General Information of the Drug

Generic Name: Fovinaciclib Citrate Capsules

Dosage Form: Capsules

Specification: 25mg, 100mg (calculated based on $C_{29}H_{40}N_8OS$)

Registration Category: Chemicals Category 1

Marketing Authorization Holder/Pharmaceutical Manufacturer: Jinzhou Avanc Pharmaceutical Co., Ltd. * (錦州奧鴻藥業有限責任公司)

Drug Approval Number: Guo Yao Zhun Zi H20250023 , Guo Yao Zhun Zi H20250024

III. Basic Information and Research Progress of the Drug

The Drug is an innovative small molecule CDK4/6 inhibitor with independent intellectual property rights owned by the Group (i.e., the Company and its subsidiaries/units, the same hereinafter), which is an orally administered, potent, highly selective, innovative small molecule drug with a structure, and was recognized as a National Major Scientific and Technological Special Project for “Significant Drugs Development” in 2018.

In addition to the newly indication approved, another indication of the Drug (in combination with Fulvestrant for the treatment of adult patients with hormone receptor (HR) positive and human epidermal growth factor receptor-2 (HER2) negative recurrent or metastatic breast cancer, who have experienced disease progression after prior endocrine therapy) has already been approved for marketing in China(excluding Hong Kong, Macao and Taiwan region for the purpose of this announcement, the same applies below) in May 2025.

As of August 2025, the Group has invested approximately RMB617 million (unaudited) in total in the research and development of the Drug at current stage.

According to the latest data from IQVIA MIDAS™¹, the sales of CDK4/6 inhibitors worldwide in 2024 were approximately US\$14.912 billion.

IV. Impact on Listed Companies and Risk Warning

The approval of this new additional indication will further enhance the Drug's market competitiveness and provide more treatment options for breast cancer patients in China.

Due to the industry characteristics of pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and

¹ Provided by IQVIA, a provider of professional medical and health information and strategic consultation services in the world.

sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

15 September 2025

** For identification purposes only*